Revolution Medicines, Inc.
RVMD
55 insider filings · Latest: Sep 29, 2026
Common Stock Transactions
| Txn Date | Accepted | Insider | Type | Shares | Avg Price | Value | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | Mar 13 11:34 PM | GOLDSMITH MARK A | Proposed Sale | 13,261 | $99.59 | $1.3M | — | View → |
| Mar 16, 2026 | Mar 13 11:31 PM | Cislini Jeff | Proposed Sale | 2,053 | $99.59 | $204.5K | — | View → |
| Mar 16, 2026 | Mar 13 11:24 PM | Anders Jack | Proposed Sale | 2,134 | $99.59 | $212.5K | — | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Sale | 36,000 | $101.23 | $3.6M | 64,424(I) | View → |
| Mar 2, 2026 | Mar 2 9:33 PM | JONATHAN GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $102.02 | $306.1K | — | View → |
| Mar 2, 2026 | Mar 2 9:33 PM | THE REBECCA GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $102.02 | $306.1K | — | View → |
| Mar 2, 2026 | Mar 2 9:32 PM | MARK A GOLDSMITH | Proposed Sale | 30,000 | $102.02 | $3.1M | — | View → |
| Jan 21, 2026 | Jan 23 9:31 PM | Jeff CisliniGeneral Counsel | Sale | 908 | $115.60 | $105.0K | 46,976(D) | View → |
| Jan 21, 2026 | Jan 21 9:23 PM | JEFFREY TODD CISLINI | Proposed Sale | 908 | $116.22 | $105.5K | — | View → |
| Jan 7, 2026 | Jan 7 9:23 PM | MARGARET A HORN | Proposed Sale | 75,000 | $79.85 | $6.0M | — | View → |
| Jan 7, 2026 | Jan 7 9:22 PM | JACK LEE ANDERS | Proposed Sale | 10,000 | $79.85 | $798.5K | — | View → |
| Dec 15, 2025 | Dec 13 2:03 AM | GOLDSMITH MARK A | Proposed Sale | 14,964 | $77.81 | $1.2M | — | View → |
| Dec 15, 2025 | Dec 13 2:00 AM | Kelsey Stephen Michael | Proposed Sale | 5,296 | $77.81 | $412.1K | — | View → |
| Dec 15, 2025 | Dec 13 1:59 AM | Cislini Jeff | Proposed Sale | 2,614 | $77.81 | $203.4K | — | View → |
| Dec 15, 2025 | Dec 13 1:57 AM | Anders Jack | Proposed Sale | 3,017 | $77.81 | $234.8K | — | View → |
| Dec 15, 2025 | Dec 13 1:55 AM | Horn Margaret A | Proposed Sale | 4,711 | $77.81 | $366.6K | — | View → |
| Nov 25, 2025 | Nov 25 9:29 PM | J H GOLDSMITH & M A GOLDSMITHCO-TTEE JONATHAN GOLDSMITH REV TRU/A/D 8/16/2023 | Proposed Sale | 3,000 | $73.66 | $221.0K | — | View → |
| Nov 25, 2025 | Nov 25 9:29 PM | THE REBECCA GOLDSMITH REVOCABLE TRUST | Proposed Sale | 3,000 | $73.66 | $221.0K | — | View → |
| Nov 25, 2025 | Nov 25 9:28 PM | MARK A GOLDSMITH | Proposed Sale | 60,000 | $73.66 | $4.4M | — | View → |
| Nov 25, 2025 | Nov 25 9:25 PM | JACK LEE ANDERS | Proposed Sale | 5,418 | $73.66 | $399.1K | — | View → |
Stock Options & Derivatives
| Txn Date | Accepted | Insider | Type | Shares | Exercise Price | Shares Owned | Filing |
|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Apr 29 9:50 PM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 3,120 | $33.62 | 109,230(D) | View → |
| Apr 15, 2026 | Apr 17 11:26 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 120,000 | $4.73 | 424,085(D) | View → |
| Mar 25, 2026 | Mar 27 12:04 AM | Anthony ManciniChief Global Commercialization Officer | Option Exercise | 37,450 | $33.62 | 112,350(D) | View → |
| Mar 1, 2026 | Mar 4 2:11 AM | Xiaolin WangEVP, Clinical Development | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:10 AM | Lin WeiChief Medical Officer | Grant/Award | 34,000 | $102.02 | 34,000(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Stephen Michael KelseyPresident, Research and Development | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 2, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 30,000 | $4.09 | 47,708(D) | View → |
| Mar 1, 2026 | Mar 4 2:09 AM | Mark A GoldsmithDirector, President and Chief Executive Officer | Grant/Award | 128,600 | $102.02 | 128,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Margaret A HornChief Operating Officer | Grant/Award | 47,600 | $102.02 | 47,600(D) | View → |
| Mar 1, 2026 | Mar 4 2:08 AM | Jeff CisliniGeneral Counsel | Grant/Award | 32,500 | $102.02 | 32,500(D) | View → |
| Mar 1, 2026 | Mar 4 2:07 AM | Jack AndersChief Financial Officer | Grant/Award | 45,400 | $102.02 | 45,400(D) | View → |
| Feb 6, 2026 | Feb 10 10:30 PM | Mark A GoldsmithDirector, President and Chief Executive Officer | Option Exercise | 24,010 | $0.54 | 144,493(D) | View → |
← Previous
Page 2 of 2